The Top 5 Biosimilar Articles for the Week of September 7

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of September 7, 2020.

Number 5: Authors of a report on Medicare spending trends said there’s more to controlling the affordability of insulin than instituting out-of-pocket (OOP) caps.

Number 4: A review of changes in business practices by PBMs states that apparent reforms have been undermined by behind-the-scenes arrangements that have stalled placement of biosimilars on formulary and slowed uptake.

Number 3: Bio-Thera Solutions has begun a phase 1 clinical trial for its proposed ustekinumab biosimilar (BAT2206), referencing Stelara, which is used in the treatment of plaque psoriasis and psoriatic arthritis.

Number 2: This summer, The Center for Biosimilars® interviewed several experts for their opinions on the current need for biosimilars and how companies are working to overcome barriers to uptake.

Number 1: Some European markets are more formidable than others with regard to complexity and getting biosimilars established, but there are good places to start, Jonathan Sweeting, head of Europe for Samsung Bioepis, explains.

To read all of these articles and more, visit centerforbiosimilars.com.